Organization (Industry)
GERON CORP
ClinicalTrials.gov lists GERON CORP as lead sponsor of 16 trials. It has 9 active development programs and 4 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 2 registered with a 2026 start date. The dashed outline is the pace from the 1 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo Geron Corporation, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers GERON CORP: 16 lead-sponsored trials and 2 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (18)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Recurrence | 5 |
| Myelodysplastic Syndromes | 4 |
| Primary Myelofibrosis | 4 |
| Breast Neoplasms | 3 |
| Multiple Myeloma | 3 |
Showing 5 of 18 disease areas.
Trials by start year as sponsor or collaborator (15)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
| 2012 | 1 |
| 2011 | 1 |
Showing 10 of 15 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (9)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Imetelstat | Primary Myelofibrosis | Phase 3 | 3 |
| Imetelstat | Polycythemia | Phase 3 | 1 |
| Best Available Therapy | Polycythemia | Phase 3 | 1 |
| Best Available Therapy | Primary Myelofibrosis | Phase 3 | 1 |
| Imetelstat | Recurrence | Phase 2/3 | 4 |
Showing 5 of 9 active programs.
Approved assets (4)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Imetelstat | 15 |
| BEVACIZUMAB | 2 |
| (nab)-paclitaxel | 1 |
| Ruxolitinib | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 2 of 3 hit target (n=3) | 1 of 2 on time (n=2) |
Journals published in (25)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Haematologica | 3 |
| Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 3 |
| The New England journal of medicine | 3 |
| Blood | 2 |
| Oncogene | 2 |
Showing 5 of 25 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 206 | 15 | 2025-10-14 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | not reported | -83,500,000 | 71,433,000 |
| 2024 | not reported | -174,572,000 | 103,738,000 |
| 2023 | 237,000 | -184,127,000 | 125,046,000 |
| 2022 | 596,000 | -141,901,000 | 95,518,000 |
| 2021 | 1,393,000 | -116,112,000 | 85,727,000 |
| 2020 | 253,000 | -75,617,000 | 51,488,000 |
| 2019 | 460,000 | -68,548,000 | 52,072,000 |
| 2018 | 1,066,000 | -27,017,000 | 13,432,000 |
| 2017 | 1,065,000 | -27,916,000 | 11,033,000 |
| 2016 | 6,162,000 | -29,537,000 | 18,047,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (32)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-05-20 | Other financing | not disclosed | Sec extracted |
| 2026-03-02 | Follow-on offering | 150,000,000 | Edgar offerings |
| 2026-01-05 | Debt financing | 125 | Sec extracted |
| 2024-11-01 | Debt financing | 125 | Sec extracted |
| 2024-11-01 | Royalty / licensing | 125,000,000 | Sec extracted |
Showing 5 of 32 events.
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Geron Corporation | Foster City, US | FDA |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (11)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| University Hospital Leipzig | Co sponsors trial with | 1 |
| Government of the United States of America | Co sponsors trial with | 1 |
| Children's Oncology Group | Co sponsors trial with | 1 |
| Groupe Francophone des Myélodysplasies | Co sponsors trial with | 1 |
| QIMR Berghofer Medical Research Institute | Co sponsors trial with | 1 |
Showing 5 of 11 relationships.
Latest dated events (262)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-10-08 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-05-20 | Financing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-03-02 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-01-05 | Debt facility | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-01-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 262 events.
Biomarker capability evidence (67)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABL1 | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| ALB | Trial collaborator | Named in trial inclusion criteria |
| BCR | Trial collaborator | Named in trial inclusion criteria |
| CBL | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 67 evidence rows.
On Scientist.com
GERON CORP is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Geron Corperation on Scientist.com
For prices, more details, or to contact Geron Corperation, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.